Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Happy to share that the manuscript of TROPIONBreast01 OS is now available in Annals of Oncology.
This was DatoDXd in HR+/HER-2neg breast cancer with 1-2 prior lines of chemo after exhausting endocrine therapy…so later line trial.”
Title: Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
Authors: B. Pistilli, K. Jhaveri, S.-A. Im, S. Pernas, M. De Laurentiis, S. Wang, N. Martínez Jañez, G. Borges, D.W. Cescon, M. Hattori, Y.-S. Lu, E. Hamilton, J. Tsurutani, K. Kalinsky, P.E. Rubini Liedke, D. Carroll, S. Khan, H.S. Rugo, B. Xu, A. Bardia
Read the Full Article.
Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02
